|
Device investigation: the device was not returned to inspiremd for investigation, a review of the production records confirmed the device met all manufacturing specifications, with no malfunction or nonconformance identified.The procedure was completed using an additional stent, and no patient harm or adverse clinical outcome was reported.An investigation was initiated to identify the underlying failure mode(s) associated with delivery system deployment complications which may result in high resistance or inability to deploy the stent.This mdr is being submitted retrospectively as part of corrections implemented through (b)(4) to ensure reporting compliance.At the time of the event, the complaint was assessed as non-reportable; however, the retrospective review determined that the event meets the reporting requirements of 21 cfr part 803 since the reported event may cause or contribute to an adverse event if it were to recur.Inspiremd's recall (recall no.Z-2330-2026), initiated on may 1, 2026, identified a delivery system issue in the cguard® prime carotid stent system.However, this event occurred prior to the initiation of the recall activities.Capa-027-25 has been initiated to further evaluate similar field-reported performance issues, and complaint trending activities remain ongoing.
|
|
It was reported that during an elective transfemoral procedure, during the deployment sequence, the cguard prime stent was advanced to the target location; however, the stent was unable to be deployed.A second stent system was then introduced and deployed successfully.A 6×30 sterling balloon was used for post dilatation.The procedure was completed successfully with no reported patient harm was reported.
|